Literature DB >> 22113592

Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.

Shun-Ichi Ariizumi1, Yoshihito Kotera, Satoshi Katagiri, Masayuki Nakano, Masakazu Yamamoto.   

Abstract

BACKGROUND: We evaluated the surgical outcomes of combined hepatocellular-cholangiocarcinoma (CHC) in relation to Allen and Lisa class and the predominance of intrahepatic cholangiocarcinoma (ICC) cells within the tumor.
METHODS: We retrospectively studied 44 patients with CHC who underwent hepatectomy between 1987 and 2010. Clinicopathologic characteristics and surgical outcomes were compared in relation to Allen and Lisa class (33 combined type, 11 mixed type) and the predominance of ICC cells within the tumor (cases in which ICC cells accounted for 50% or less of all cells within the tumor, n = 22; cases in which ICC cells accounted for more than 50%, n = 22).
RESULTS: The survival rate for 42 patients with CHC who underwent curative surgery was 24% at 5 years, and median survival was 15.4 months. According to Allen and Lisa class, the number of cases with portal invasion was far higher in patients with the mixed type than in patients with the combined type. The 5-year survival rates of patients with the combined type and mixed type who underwent curative surgery were 27% and 13%, respectively, showing no statistically significant difference. According to the predominance of ICC cells, there was no difference in clinicopathologic findings between the groups. The 5-year survival rates of patients with ≤50% and >50% ICC cells within the tumor who underwent curative surgery were 21% and 26%, respectively, showing no statistically significant difference.
CONCLUSIONS: CHC had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of ICC cells within the tumor.

Entities:  

Mesh:

Year:  2011        PMID: 22113592     DOI: 10.1245/s10434-011-2150-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Authors:  Shun-ichi Ariizumi; Masakazu Yamamoto
Journal:  Surg Today       Date:  2014-09-25       Impact factor: 2.549

3.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

Review 4.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

5.  Concurrent occurrence of primary hepatocellular and cholangiocellular carcinoma in the different part of the liver: a case report.

Authors:  Xinying Li; Wei Jiang; Tiecheng Feng; Zhiming Wang
Journal:  Int J Clin Exp Med       Date:  2012-08-22

Review 6.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

7.  Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2018-10-17

8.  Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.

Authors:  Jung Il Lee; Jin-Woo Lee; Joon Mee Kim; Ja Kyung Kim; Hyun Jung Chung; Young Soo Kim
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

9.  CD44 expression in patients with combined hepatocellular cholangiocarcinoma.

Authors:  Ryounggo Kim; Sang Bum Kim; Eung-Ho Cho; Sun Hoo Park; Sung Bae Park; Seong Kweon Hong; Gibong Chae
Journal:  Ann Surg Treat Res       Date:  2015-06-11       Impact factor: 1.859

10.  Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy.

Authors:  Shun-Ichi Ariizumi; Yoshihito Kotera; Satoshi Katagiri; Masayuki Nakano; Yasuni Nakanuma; Akiko Saito; Masakazu Yamamoto
Journal:  Ann Surg Oncol       Date:  2014-03-17       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.